Nondestructive and noninvasive neutron assays are essential applications of neutron techniques.Neutron resonance transmission analysis(NRTA)is a powerful nondestructive method for investigating the elemental compositi...Nondestructive and noninvasive neutron assays are essential applications of neutron techniques.Neutron resonance transmission analysis(NRTA)is a powerful nondestructive method for investigating the elemental composition of an object.The back-streaming neutron line(Back-n)is a newly built time-of-flight facility at the China Spallation Neutron Source(CSNS)that provides neutrons in the eV to 300 MeV range.A feasibility study of the NRTA method for nuclide identification was conducted at the CSNS Back-n via two test experiments.The results demonstrate that it is feasible to identify different elements and isotopes in samples using the NRTA method at Back-n.This study reveals its potential future applications.展开更多
BACKGROUND Portal vein tumor thrombus(PVTT)is a common complication,accounting for 44%-62.2%of Hepatocellular carcinoma(HCC),and often indicates the poor prognosis.There is no global consensus for the treatment of unr...BACKGROUND Portal vein tumor thrombus(PVTT)is a common complication,accounting for 44%-62.2%of Hepatocellular carcinoma(HCC),and often indicates the poor prognosis.There is no global consensus for the treatment of unresectable HCC with PVTT.In the present case,we reported a novel strategy of radiotherapyantiangiogenesis-immune checkpoint blockade combination,which showed better response and prolonged survival.CASE SUMMARY A 51-year-old male diagnosed with HCC(Child-Pugh class A),chronic hepatitis B virus infection and Cheng’s type III PVTT,was given radiotherapy to part of the lesion plus targeted therapy as the first-line therapy,and achieved partial remission.After radiotherapy,lenvatinib plus pembrolizumab was used as maintenance therapy,and complete remission was achieved.The patient remains alive 46 months after the diagnosis of the HCC with PVTT.CONCLUSION This case of unresectable HCC patient with PVTT treated by radiation-lenvatinibpembrolizumab combination therapy shows apparent clinical efficacy,which demonstrates that local radiotherapy plus antiangiogenesis and immune checkpoint blockad could also benefit patients with advanced HCC.展开更多
目的:观察关节镜下带骨膜髂骨移植联合富血小板血浆(platelet-rich plasma,PRP)凝胶注射治疗HeppleV型距骨骨软骨损伤(osteochondral lesion of the talus,OLT)的临床疗效和安全性。方法:2019年1月至2022年8月,采用关节镜下带骨膜髂骨...目的:观察关节镜下带骨膜髂骨移植联合富血小板血浆(platelet-rich plasma,PRP)凝胶注射治疗HeppleV型距骨骨软骨损伤(osteochondral lesion of the talus,OLT)的临床疗效和安全性。方法:2019年1月至2022年8月,采用关节镜下带骨膜髂骨移植联合PRP凝胶注射治疗HeppleV型OLT患者24例。男14例,女10例。年龄16~55岁,中位数32岁。病程6~18个月,中位数14个月。测量手术前后的踝关节活动度。采用疼痛视觉模拟量表(visual analogue scale,VAS)评分评价足部疼痛情况,采用美国足与踝关节协会(American Orthopedic Foot and Ankle Society,AOFAS)踝与后足评分标准评价踝关节功能。术后随访观察并发症发生情况。结果:所有患者均获随访,随访时间12~30个月,中位数20个月。术后1例患者出现小腿肌间静脉血栓,经对症治疗后好转。所有患者均未出现神经损伤和切口感染。踝关节活动度,术前42.16°±5.88°、术后1个月52.28°±7.24°、术后3个月58.44°±8.46°、末次随访时62.36°±10.24°。足部疼痛VAS评分,术前(5.88±1.48)分、术后1个月(3.64±1.20)分、术后3个月(2.12±0.88)分、末次随访时(1.24±0.68)分。AOFAS踝与后足评分,术前(52.22±9.46)分、术后1个月(78.28±7.24)分、术后3个月(84.48±6.68)分、末次随访时(90.44±6.44)分。结论:关节镜下带骨膜髂骨移植联合PRP凝胶注射治疗HeppleV型OLT,可以增加踝关节活动范围、减轻足部疼痛、促进踝关节功能恢复,且安全性较高。展开更多
基金This work was supported by the National Natural Science Foundation of China(No.12035017)Youth Innovation Promotion Association CAS(No.2023014)Guangdong Basic and Applied Basic Research Foundation(Nos.2020A1515010360 and 2022B1515120032).
文摘Nondestructive and noninvasive neutron assays are essential applications of neutron techniques.Neutron resonance transmission analysis(NRTA)is a powerful nondestructive method for investigating the elemental composition of an object.The back-streaming neutron line(Back-n)is a newly built time-of-flight facility at the China Spallation Neutron Source(CSNS)that provides neutrons in the eV to 300 MeV range.A feasibility study of the NRTA method for nuclide identification was conducted at the CSNS Back-n via two test experiments.The results demonstrate that it is feasible to identify different elements and isotopes in samples using the NRTA method at Back-n.This study reveals its potential future applications.
文摘BACKGROUND Portal vein tumor thrombus(PVTT)is a common complication,accounting for 44%-62.2%of Hepatocellular carcinoma(HCC),and often indicates the poor prognosis.There is no global consensus for the treatment of unresectable HCC with PVTT.In the present case,we reported a novel strategy of radiotherapyantiangiogenesis-immune checkpoint blockade combination,which showed better response and prolonged survival.CASE SUMMARY A 51-year-old male diagnosed with HCC(Child-Pugh class A),chronic hepatitis B virus infection and Cheng’s type III PVTT,was given radiotherapy to part of the lesion plus targeted therapy as the first-line therapy,and achieved partial remission.After radiotherapy,lenvatinib plus pembrolizumab was used as maintenance therapy,and complete remission was achieved.The patient remains alive 46 months after the diagnosis of the HCC with PVTT.CONCLUSION This case of unresectable HCC patient with PVTT treated by radiation-lenvatinibpembrolizumab combination therapy shows apparent clinical efficacy,which demonstrates that local radiotherapy plus antiangiogenesis and immune checkpoint blockad could also benefit patients with advanced HCC.
文摘目的:观察关节镜下带骨膜髂骨移植联合富血小板血浆(platelet-rich plasma,PRP)凝胶注射治疗HeppleV型距骨骨软骨损伤(osteochondral lesion of the talus,OLT)的临床疗效和安全性。方法:2019年1月至2022年8月,采用关节镜下带骨膜髂骨移植联合PRP凝胶注射治疗HeppleV型OLT患者24例。男14例,女10例。年龄16~55岁,中位数32岁。病程6~18个月,中位数14个月。测量手术前后的踝关节活动度。采用疼痛视觉模拟量表(visual analogue scale,VAS)评分评价足部疼痛情况,采用美国足与踝关节协会(American Orthopedic Foot and Ankle Society,AOFAS)踝与后足评分标准评价踝关节功能。术后随访观察并发症发生情况。结果:所有患者均获随访,随访时间12~30个月,中位数20个月。术后1例患者出现小腿肌间静脉血栓,经对症治疗后好转。所有患者均未出现神经损伤和切口感染。踝关节活动度,术前42.16°±5.88°、术后1个月52.28°±7.24°、术后3个月58.44°±8.46°、末次随访时62.36°±10.24°。足部疼痛VAS评分,术前(5.88±1.48)分、术后1个月(3.64±1.20)分、术后3个月(2.12±0.88)分、末次随访时(1.24±0.68)分。AOFAS踝与后足评分,术前(52.22±9.46)分、术后1个月(78.28±7.24)分、术后3个月(84.48±6.68)分、末次随访时(90.44±6.44)分。结论:关节镜下带骨膜髂骨移植联合PRP凝胶注射治疗HeppleV型OLT,可以增加踝关节活动范围、减轻足部疼痛、促进踝关节功能恢复,且安全性较高。
